Organon & Co.
OGN Healthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OGN
Organon & Co. (OGN) EV/Sales
As of 16 October 2026, Organon & Co. (OGN) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from 1.3× (June 2021) to 2.9× (March 2022); the current reading is higher than 30% of that period. That is below the Drug Manufacturers General industry median of 4.0× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.6× | (15.04%) |
| FY2024 | 1.9× | (0.38%) |
| FY2023 | 1.9× | (24.03%) |
| FY2022 | 2.5× | (2.82%) |
| FY2021 | 2.6× | 71.57% |
| FY2020 | 1.5× | 0.00% |
| FY2019 | 1.5× | 0.00% |
| FY2018 | 1.5× | 0.00% |
| FY2017 | 1.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.8× | 22.50% |
| Mar 2026 | 1.5× | (8.46%) |
| Dec 2025 | 1.6× | (7.92%) |
| Sep 2025 | 1.7× | 0.78% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AMRN Amarin Corporation PLC compare | −0.3× |
| GRFS Grifols, S.A. compare | 1.8× |
| OGN Organon & Co. | 1.8× |
| SNY Sanofi compare | 2.0× |
| GSK GSK PLC Sponsored ADR compare | 2.7× |
| BMY Bristol Myers Squibb Company compare | 3.1× |
| PFE Pfizer Inc. compare | 3.5× |
| NVO Novo Nordisk A/S compare | 3.6× |
| BIIB Biogen Inc. compare | 4.0× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)